BioXcel Therapeutics prices IPO at $11, the low end of the range

Shutterstock photo

BioXcel Therapeutics, which is developing new uses of drugs to treat neurological disorders and cancer, raised $60 million by offering 5.5 million shares at $11, the low end of the range of $11 to $13. BioXcel Therapeutics plans to list on the Nasdaq under the symbol BTAI. Barclays, UBS Investment Bank and BMO Capital Markets acted as lead managers on the deal.

The article BioXcel Therapeutics prices IPO at $11, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?